These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma. Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316 [TBL] [Abstract][Full Text] [Related]
9. Overview and management of cardiac and pulmonary adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib. Wang M; Cheng J Oncology (Williston Park); 2013 Dec; 27 Suppl 3():24-30. PubMed ID: 25184233 [TBL] [Abstract][Full Text] [Related]
10. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Thompson JL Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152 [TBL] [Abstract][Full Text] [Related]
11. Carfilzomib: a next-generation proteasome inhibitor for multiple myeloma treatment. Bilotti E Clin J Oncol Nurs; 2013 Apr; 17(2):E35-44. PubMed ID: 23538263 [TBL] [Abstract][Full Text] [Related]
12. Arterial Hypertension and Multiple Myeloma: Physiopathology and Cardiovascular Risk and 'Practical' Indications in Patients Receiving Carfilzomib. Milan A; Bruno G; Maffei I; Iannaccone A; Ravera A; Schiavone D; Veglio F Curr Hypertens Rev; 2019; 15(1):47-53. PubMed ID: 29886833 [TBL] [Abstract][Full Text] [Related]
13. A practical review on carfilzomib in multiple myeloma. Muchtar E; Gertz MA; Magen H Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241 [TBL] [Abstract][Full Text] [Related]
14. Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events. Sandy EB; Weerasinghe C; Terjanian T J Pharm Pract; 2020 Apr; 33(2):213-216. PubMed ID: 30278813 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy. Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365 [TBL] [Abstract][Full Text] [Related]
16. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma. Salvini M; Bonello F; Boccadoro M; Larocca A Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203 [TBL] [Abstract][Full Text] [Related]
17. Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials. Wongsaengsak S; Kopel J; Behera TR; Chakraborty R; Ball S Br J Haematol; 2020 Jul; 190(2):e95-e97. PubMed ID: 32400886 [No Abstract] [Full Text] [Related]
18. Heart failure secondary to carfilzomib-induced heart block in multiple myeloma patients. Tjionas H; Gupta AK J Oncol Pharm Pract; 2017 Mar; 23(2):152-156. PubMed ID: 26786028 [TBL] [Abstract][Full Text] [Related]
19. Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: Early in vivo cardiovascular effects. Gavazzoni M; Lombardi CM; Vizzardi E; Gorga E; Sciatti E; Rossi L; Belotti A; Rossi G; Metra M; Raddino R Eur J Pharmacol; 2018 Nov; 838():85-90. PubMed ID: 30201379 [TBL] [Abstract][Full Text] [Related]
20. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]